Skip to main content
SpringerLink
Log in

Low molecular weight heparin (LMWH) is associated with reduced total direct medical costs in patients with venous thromboembolism

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. sanofi-aventis.Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractioned Heparin (UFH). Media Release: 10 Dec 2007. Available from: URL: http://www.sanofi-aventis.us

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Low molecular weight heparin (LMWH) is associated with reduced total direct medical costs in patients with venous thromboembolism. Pharmacoecon. Outcomes News 543, 5 (2007). https://doi.org/10.2165/00151234-200705430-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705430-00013

Keywords

Search

Navigation